Usefulness of essential phospholipids in the treatment of non-alcoholic fatty liver disease patients. Commentary to the article Commentary
Article Sidebar
Published:
Dec 31, 2018
Keywords:
non-alcoholic fatty liver disese, fatty liver, non-alcoholic steatohepatitis, essential phospholipids
Main Article Content
Abstract
Non-alcoholic fatty liver disease is one of the most common of chronic liver diseases. The incidence of its occurrence is constantly increasing due to the prevalence of overweight, obesity and a sedentary lifestyle. Treatment of this disease consists mainly of lifestyle modifications, weight loss and treatment of co-morbidities. Essential phospholipids, which have a beneficial effect on improving the quality of life of patients, reduce transaminases, reduce the severity of steatosis, inflammatory changes and even fibrosis in the liver, may help in the treatment. No side effects associated with the use of essential phospholipids have been observed so far.
Article Details
How to Cite
Ciećko-Michalska, I. (2018). Usefulness of essential phospholipids in the treatment of non-alcoholic fatty liver disease patients. Commentary to the article. Medycyna Faktow (J EBM), 11(4(41), 294-298. https://doi.org/10.24292/01.MF.0418.6
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Younossi Z.M., Koenig A.B., Abdelatif D. et al.: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1): 73-84.
2. Chalasani N., Younossi Z., Lavine J.E. et al.: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328-357.
3. Gundermann K.J., Kuenker A., Kuntz E. et al.: Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol. Rep. 2011; 63(3): 643-659.
4. Dajani A.I., Abu Hammour A.M., Zakaria M.A. et al.: Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab. J. Gastroenterol. 2015; 16(3-4): 99-104.
2. Chalasani N., Younossi Z., Lavine J.E. et al.: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328-357.
3. Gundermann K.J., Kuenker A., Kuntz E. et al.: Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol. Rep. 2011; 63(3): 643-659.
4. Dajani A.I., Abu Hammour A.M., Zakaria M.A. et al.: Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab. J. Gastroenterol. 2015; 16(3-4): 99-104.